| Dr James Wallentine Blotter, MD | |
|
2245 N 400 E, Ste 301, North Logan, UT 84341-1892 | |
| (435) 753-7880 | |
| (435) 753-5845 |
| Full Name | Dr James Wallentine Blotter |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 29 Years |
| Location | 2245 N 400 E, North Logan, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962499673 | NPI | - | NPPES |
| M-8784 | Other | ID | IDAHO STATE LICENSE |
| 87037196400 | Medicaid | UT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0007X | Otolaryngology - Plastic Surgery Within The Head & Neck | 3082587-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Logan Regional Hospital | Logan, UT | Hospital |
| Cache Valley Hospital | North logan, UT | Hospital |
| Bear River Valley Hospital | Tremonton, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cache Valley Ear Nose And Throat, Pllc | 5193128882 | 8 |
| Cache Valley Ear Nose And Throat, Pllc | 5193128882 | 8 |
News Archive
The Senate Thursday afternoon passed a health care reform reconciliation bill and sent the bill back to the House for final consideration. The bill passed 56-43.
Pharmaceutical company Merck (MSD) announced Monday it has "awarded a grant to PATH, a global health nonprofit, to identify game-changing technologies with the potential to save the lives of women during pregnancy and childbirth in low-resource settings," according to a Merck press release.
Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
While prostate cancer is a very common diagnosis, it is a deadly disease in relatively few men. One in 6 men will develop prostate cancer during his lifetime. However, of these, only one in 10 cases will be life-threatening.
› Verified 1 days ago
| Entity Name | Cache Valley Ear Nose & Throat, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548303795 PECOS PAC ID: 5193128882 Enrollment ID: O20220216002175 |
News Archive
The Senate Thursday afternoon passed a health care reform reconciliation bill and sent the bill back to the House for final consideration. The bill passed 56-43.
Pharmaceutical company Merck (MSD) announced Monday it has "awarded a grant to PATH, a global health nonprofit, to identify game-changing technologies with the potential to save the lives of women during pregnancy and childbirth in low-resource settings," according to a Merck press release.
Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
While prostate cancer is a very common diagnosis, it is a deadly disease in relatively few men. One in 6 men will develop prostate cancer during his lifetime. However, of these, only one in 10 cases will be life-threatening.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Wallentine Blotter, MD 2245 N 400 E, Ste 301, North Logan, UT 84341-1892 Ph: (435) 753-7880 | Dr James Wallentine Blotter, MD 2245 N 400 E, Ste 301, North Logan, UT 84341-1892 Ph: (435) 753-7880 |
News Archive
The Senate Thursday afternoon passed a health care reform reconciliation bill and sent the bill back to the House for final consideration. The bill passed 56-43.
Pharmaceutical company Merck (MSD) announced Monday it has "awarded a grant to PATH, a global health nonprofit, to identify game-changing technologies with the potential to save the lives of women during pregnancy and childbirth in low-resource settings," according to a Merck press release.
Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
While prostate cancer is a very common diagnosis, it is a deadly disease in relatively few men. One in 6 men will develop prostate cancer during his lifetime. However, of these, only one in 10 cases will be life-threatening.
› Verified 1 days ago
Zachary Robinett, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2245 N 400 E, Ste 301, North Logan, UT 84341 Phone: 435-753-7880 Fax: 435-753-5845 | |
Dr. Jeffrey Green Bennion, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2245 N 400 E, Ste 301, North Logan, UT 84341 Phone: 435-753-7880 Fax: 435-753-5845 |